FindTrial
Sign In

The efficacy and safety of anlotinib with or without PD-1 inhibitors in the treatment of advanced liver cancer: a retrospective real-world study

The efficacy and safety of anlotinib with or without PD-1 inhibitors in the treatment of advanced liver cancer: a retrospective real-world study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100054806
Enrollment
Unknown
Registered
2021-12-27
Start date
2021-12-27
Completion date
Unknown
Last updated
2022-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Case series:No

Sponsors

The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Patients with HCC who meet the clinical diagnostic criteria of the "Standards for the Diagnosis and Treatment of Primary Liver Cancer" (2019 Edition) or diagnosed by histopathological or cytological examinations. And the patient cannot receive radical surgery; 3. There are measurable lesions; 4. Anlotinib has been used or is currently being used (the dose is not limited); 5. The case information is complete.

Exclusion criteria

Exclusion criteria: Anlotinib (8-12mg d1-14 q3w) can be used for less than two cycles.

Design outcomes

Primary

MeasureTime frame
Effect and safety;—

Countries

China

Contacts

Public ContactChen Xiaoqi

The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine

28050827@qq.com+86 18538193183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026